Elite in Small Cell Lung Cancer (SCLC)

Dr. Christine L. Hann

Hematology Oncology | Oncology
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Elite in Small Cell Lung Cancer (SCLC)
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christine Hann is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is currently accepting new patients.

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 31 articles and participated in 4 clinical trials in the study of Small Cell Lung Cancer (SCLC).

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Navitoclax, Osimertinib
Study Phase: Phase 1
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Biological, Drug
Study Drugs: Navitoclax, Vistusertib
Study Phase: Phase 1/Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

89 Total Publications

Twist1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of Twist1.
Twist1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of Twist1.
Journal: Neoplasia (New York, N.Y.)
Published: March 14, 2025
Similar Doctors
Elite in Small Cell Lung Cancer (SCLC)
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology
Elite in Small Cell Lung Cancer (SCLC)
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-1230
Languages Spoken:
English, German, Spanish, Yoruba
See accepted insurances
Accepting New Patients

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Elite in Small Cell Lung Cancer (SCLC)
Dr. Stephen V. Liu
Oncology | Hematology
Elite in Small Cell Lung Cancer (SCLC)
Dr. Stephen V. Liu
Oncology | Hematology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Liu is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Liu is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Liu is currently accepting new patients.

Distinguished in Small Cell Lung Cancer (SCLC)
Dr. Patrick M. Forde
Hematology Oncology | Oncology
Distinguished in Small Cell Lung Cancer (SCLC)
Dr. Patrick M. Forde
Hematology Oncology | Oncology
401 North Broadway, Weinberg Bdg., 
Baltimore, MD 
 (0.1 miles away)
410-955-3974
Languages Spoken:
English, Irish
See accepted insurances
Accepting New Patients

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Small Cell Lung Cancer (SCLC). Dr. Forde is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hann's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile